Allergan Inc.'s second-quarter earnings rose 20% though a strong dollar weighed on revenue growth at the maker of Botox and medical devices. For the year, the company narrowed its guidance and now expects per-share earnings of $4.15 to $4.19 and product sales of $5.65 billion to $5.8 billion, compared with its prior estimate for $4.13 to $4.19 and $5.65 billion to $5.85 billion. For the current quarter, the company expects per-share earnings below analysts' expectations of $1.02 to $1.04 on revenue of $1.37 billion to $1.45 million. Analysts polled by Thomson Reuters most recently expected $1.06 and $1.44 billion, respectively.
